Contact
Please use this form to send email to PR contact of this press release:
Biomed Industries, Inc. to Present Phase 2 Results on NA-931—An Oral Alternative to Injectables for Obesity—at ADA 2025
TO:
Michael Willis
Biomed Industries, Inc.
+1 800-824-5135